Actelion plans buyback amid takeover buzz

With its slumping share price revived by persistent rumors of a possible takeover, Actelion announced plans to buy back up to $827 million shares in the next three years. The Swiss biotech insists that it also wants to remain independent, but that hasn't blunted investors' enthusiasm for a deal. Story

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.